Adaptive Biotechnologies (ADPT) Consolidated Net Income (2018 - 2026)

Adaptive Biotechnologies has reported Consolidated Net Income for 9 years, with the latest figure at -$53.0 million in Q1 2026.

• Quarterly Consolidated Net Income fell 77.12% year-over-year to -$53.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$181.2 million (down 30.07% YoY) and the FY2025 annual result came in at -$62.0 million, up 61.67% from the prior year.
• Consolidated Net Income retreated to -$53.0 million in Q1 2026 per ADPT's latest filing, from -$14.4 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $9.5 million in Q3 2025 and troughed at -$208.7 million in Q1 2022.
• A 5-year average of -$56.3 million and a median of -$48.2 million in 2024 frame the typical range for Consolidated Net Income.
• The widest YoY moves for Consolidated Net Income: up 129.74% in 2025, down 166.51% in 2025.
• Over 5 years, Consolidated Net Income stood at -$38.9 million in 2022, then tumbled by 78.65% to -$69.5 million in 2023, then jumped by 55.37% to -$31.0 million in 2024, then surged by 53.42% to -$14.4 million in 2025, then plunged by 267.09% to -$53.0 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$53.0 million, -$14.4 million, and $9.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.